Education
About Us
Working with TipRanks
Follow Us
Paul Berns Insider Profile
4 Followers
Paul Berns, President & CEO, Director at Anacor Pharmaceuticals, holds 7.80M shares in Neumora Therapeutics, Inc. (Ticker: NMRA), holds 9.27M shares in Metsera, Inc. (Ticker: MTSR), holds 0.00 shares in EQRx, Inc. (Ticker: EQRX).
Paul Berns Anacor Pharmaceuticals (~ANAC)President & CEO, Director
Anacor Pharmaceuticals (~ANAC)
President & CEO, Director
Ranked #54,916 out of 100,956 Corporate Insiders
Profitable Transactions
4 out of 10 Profitable Transactions
Average Return
-1.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Paul Berns holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Aug 11, 2015 - Aug 11, 2016
Return:+22.70%
The most profitable trade made by Paul Berns
Paul Berns's Trading History
Anacor Pharmaceuticals
Jun 24, 2016
―
Uninformative Sell
22.96M
$26.53M
Unity Biotechnology
May 07, 2018
Director
Uninformative Buy
―
$5.48K
VYNE Therapeutics
―
Director
―
―
EQRx, Inc.
Nov 09, 2023
―
Uninformative Sell
―
$0.00
Neumora Therapeutics, Inc.
Feb 20, 2025
CEO and COB, Director
Uninformative Sell
23.44K
$11.63M
Metsera, Inc.
Feb 03, 2025
Director
Uninformative Buy
―
$236.14M
Jazz Pharmaceuticals
Aug 09, 2021
Director
Informative Sell
223.30K
$1.15M
XenoPort
May 21, 2015
―
Uninformative Buy
―
$70.70K
Cellectar Biosciences
Apr 21, 2016
Director
Informative Buy
248.83K
$0.00
List of latest transactions for each holding click on a transaction to see Paul Berns's performance on stock
You May Also Like
Paul Berns insider profile FAQ
What is the percentage of profitable transactions made by Paul Berns?
The percentage of profitable transactions made by Paul Berns is 40%.
What is the average return per transaction made by Paul Berns?
The average return per transaction made by Paul Berns is -1.60%.
What stocks does Paul Berns hold?
Paul Berns holds: ~ANAC, UBX, VYNE, EQRX, NMRA, MTSR, JAZZ, XNPT, CLRB stocks.
What was Paul Berns’s latest transaction?
Paul Berns latest transaction was an Uninformative Sell of $23.44K.
What was Paul Berns's most profitable transaction?
Paul Berns’s most profitable transaction was an Informative Sell of JAZZ stock on August 11, 2015. The return on the trade was 22.70%.
What is Paul Berns's role in Anacor Pharmaceuticals?
Paul Berns's role in Anacor Pharmaceuticals is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.